New inhaled therapy for lung scarring enters early human testing
Symptom relief
Recruiting now
This early-stage study tests an inhaled form of nintedanib (MNKD-201) in 24 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal is to check safety and how the body handles the drug. Participants receive either the drug or a placebo, and researc…
Phase: PHASE1 • Sponsor: Mannkind Corporation • Aim: Symptom relief
Last updated May 01, 2026 15:59 UTC